Cheng Chun-Yao, Hao Wen-Rui, Cheng Tzu-Hurng
Department of Ophthalmology, Cathay General Hospital, Taipei 10633, Taiwan.
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan.
World J Methodol. 2025 Jun 20;15(2):98912. doi: 10.5662/wjm.v15.i2.98912.
This editorial offers insights from a minireview by Venkatesh , who explored pharmacological adjuvants for diabetic vitrectomy. Specifically, they synthesized current knowledge and evaluated the efficacy of various adjunctive therapies in improving the outcomes of diabetic retinopathy and managing associated complications. Herein, we highlight the key roles of pharmacological adjuvants in optimizing surgical techniques, minimizing intraoperative challenges, and enhancing postoperative recovery. We further discuss the potential implications of this approach for clinical practice and future research directions in this evolving field. Overall, this editorial underscores the importance of incorporating pharmacological adjuvants into standard diabetic vitrectomy care to improve surgical outcomes and thus patients' quality of life.
这篇社论提供了文卡特什一篇短文综述中的见解，他探讨了糖尿病玻璃体切除术的药理学辅助剂。具体而言，他们综合了当前的知识，并评估了各种辅助治疗在改善糖尿病视网膜病变结局和管理相关并发症方面的疗效。在此，我们强调药理学辅助剂在优化手术技术、减少术中挑战以及促进术后恢复方面的关键作用。我们进一步讨论了这种方法对临床实践的潜在影响以及这个不断发展的领域未来的研究方向。总体而言，这篇社论强调了将药理学辅助剂纳入标准糖尿病玻璃体切除术护理以改善手术结局从而提高患者生活质量的重要性。
